Microsoft word - document2

For Immediate Release November 15th, 2011 James Murphy Has Brain Tumor Relapse; Donations Welcome

James Murphy, former guitarist of both Death and Testament, As well as founding
member of the death metal band Disincarnate, has had a relapse of the brain tumor that
sidelined him back in 2001. Murphy stated that the tumor had returned but that it was a
non malignant and that it was being treated pharmacologically. Unfortunately, those
medications have serious side effects that have left him unable to work. The option for
different medications is available, but at a cost of over $1000 a month, and he needs a
minimum of 6 months of medication for treatment to be effective. With his medical
expenses extremely high and James not being able to work due to the side effects of the
current medications, the metal community is being asked to come together and help one
of their brothers and donate to help him beat this once and for all.
In August 2001, Murphy was discovered to have a massive tumor growth near the base
of his brain (on the pituitary gland) and was quickly scheduled for an urgent life-saving
operation. James underwent surgery on September 17, 2001, involving a Maxillary
Swing procedure that made entry through the left side of the face. An incision was made
underneath the left eye, along the side of the nose, and finally through the middle of the
upper lip. The facial tissue was then pulled back and the cheekbone removed. They then
cut through James' sinus and made entry below the orbit of the eye to remove a portion
of the growth. More was removed through an incision made in the soft pallet inside the
mouth. About 70% of the tumor was removed, the remainder being too close to vital
structures to risk further damage. The sinus was then packed with fat tissue taken from
the lower abdomen via an incision below the navel and reattached. The cheekbone was
set back in place and held with two small titanium plates. The facial tissue was then
sutured closed along with the soft pallet. His mouth was fitted with prosthesis to protect
the pallet tissue while it healed. The remaining 30% of the tumor was treated with a
medication called Parlodel (Bromocriptine) to shrink it called which James was told he
would have to take for the rest of his life. This treatment was more or less successful for
9 years.
A spike in the hormone indicator for the tumor, as discovered by a blood test that was
followed up by an MRI to confirm, showed that the tumor was again active, and had
grown a bit. Luckily not enough to require surgery, but radiation treatment was still on
the table. The decision was made to defer the radiation treatment for 6 months, during
which time the tumor would be attacked pharmacologically, increasing the dose of the
drug used to hinder its growth to a level which leaves James wiped out, overly fatigued,
nauseous, and unable to work to earn his living at full capacity. A better drug, one that
has less side-effects, and would require a much smaller dosage is available, but
considerable vastly more expensive.
Click Here to Donate:  For additional information, please contact Adrenaline PR and Maria Ferrero at 732-462-4262 or


EUROPEAN ORGANISATION FOR THE SAFETY OF AIR NAVIGATION EUROCONTROL This document is issued as EATCHIP Reference Material. The contents are not mandatory. They provide information and explanation or may indicate best practice. Human Factors Module HUM.ET1.ST13.2000-REP-01 Edition Date 15.03.1996 Released Issue EUROPEAN AIR TRAFFIC CONTROL HARMONISATION AND INTEGRATI

UPDATED PROTOCOL OF THE EUROCARE HIGH RESOLUTION STUDIES ON CARE OF CANCER PATIENTS INTRODUCTION Eurocare is a “Concerted Action” of European population-based cancer registries (CRs) which deals with survival and care of cancer patients. On the basis of the past experience of Eurocare, the collection of some clinical variables (stage and basic diagnostic investigations p

Copyright © 2014 Articles Finder